Compounders Research Compare

Pharvaris N.V.(PHVS)

Biotechnology · Zug, ZH

$30.88+0.39 (+1.26%)

Delayed quote: Oct 6, 2026, 3:15 PM EDT

About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Zug, ZH

148 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Berndt Modig

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T19:18:06.600Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:18:06.600Z.

Quote observation: 2026-10-06T19:15:26.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 2,157,536,540
TTM free cash flow · period ending 2026-06-30: -181,122,578.92948

FMP input reference: 2e72a758e634708c28c06ae15f1e09243225437df43ff658102191b35b06d910

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PHVS Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

PHVS Competitors' Price/FCF Ratio

Pharvaris N.V.

Current

Market Cap

$2.16B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GeneDx Holdings Corp.

Market Cap

$2.13B

Price/FCF Ratio

N/A

TTM Avg

1575.22

3Y Avg

1575.22

5Y Avg

1575.22

SELLAS Life Sciences Group, Inc.

Market Cap

$2.13B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Maravai LifeSciences Holdings, Inc.

Market Cap

$2.20B

Price/FCF Ratio

N/A

TTM Avg

6.98

3Y Avg

9.73

5Y Avg

13.98

Addus HomeCare Corporation

Market Cap

$2.11B

Price/FCF Ratio

13.78

TTM Avg

17.53

3Y Avg

17.89

5Y Avg

19.30

Vera Therapeutics, Inc.

Market Cap

$2.08B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alvotech

Market Cap

$2.08B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Alamar Biosciences, Inc.

Market Cap

$2.24B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Celldex Therapeutics, Inc.

Market Cap

$2.07B

Price/FCF Ratio

N/A

TTM Avg

9.03

3Y Avg

8.56

5Y Avg

8.56

Vericel Corporation

Market Cap

$2.06B

Price/FCF Ratio

41.45

TTM Avg

42.75

3Y Avg

385.34

5Y Avg

202.04

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Pharvaris N.V. (PHVS)	$2.16B	N/A	N/A	N/A	N/A
GeneDx Holdings Corp. (WGS)vs ›	$2.13B	N/A	1575.22	1575.22	1575.22
SELLAS Life Sciences Group, Inc. (SLS)vs ›	$2.13B	N/A	N/A	N/A	N/A
Maravai LifeSciences Holdings, Inc. (MRVI)vs ›	$2.20B	N/A	6.98	9.73	13.98
Addus HomeCare Corporation (ADUS)vs ›	$2.11B	13.78	17.53	17.89	19.30
Vera Therapeutics, Inc. (VERA)vs ›	$2.08B	N/A	N/A	N/A	N/A
Alvotech (ALVO)vs ›	$2.08B	N/A	N/A	N/A	N/A
Alamar Biosciences, Inc. (ALMR)vs ›	$2.24B	N/A	N/A	N/A	N/A
Celldex Therapeutics, Inc. (CLDX)vs ›	$2.07B	N/A	9.03	8.56	8.56
Vericel Corporation (VCEL)vs ›	$2.06B	41.45	42.75	385.34	202.04

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics